www.fdanews.com/articles/142869-septrx-reports-first-20-patients-have-been-enrolled-in-its-ldquo-intersept-rdquo-ce-mark-trial-of-the-septrx-intrapocket-pfo-occluder
SeptRx Reports First 20 Patients Have Been Enrolled in its “InterSEPT” CE Mark Trial of the SeptRx Intrapocket PFO Occluder
January 3, 2012
SeptRx reported that it has completed enrollment of the first 20 patients in its ongoing “InterSEPT” clinical trial at Sankt Katharinen Hospital (Frankfurt, Germany).
MarketWatch
MarketWatch